Jason Dinges

DeepCure discovers transformative small molecule therapies for immune and inflammatory diseases. The company uses a chemistry platform that combines AI, physics-based tools and automated chemical synthesis to identify truly novel molecules that address unsolved challenges in drug discovery. The pipeline includes an oral STAT6 program with multiple novel scaffolds and an oral BRD4(BD2) program with the first truly selective inhibitor. DeepCure expects to start in clinical trials in 2025.

FlyteHealth is a tech-enabled healthcare services organization born of the belief that everyone deserves to live a healthy life. Our efforts to bring the most effective health care to people with obesity, while making it cost-efficient to do so, mean that more people can transform their health for the better—now and for the rest of their lives. We were founded by physicians who were the first to recognize obesity not as a simple issue of willpower, but as a complex disease that requires expert medical treatment. Based on their decades of research and caring for patients, our clinically proven approach combines the latest in personalized medication therapy and behavior coaching that not only helps people lose weight for the long term, but significantly improves related conditions. Our obesity treatment platform, powered by Flyte Intelligence, is built from the largest data set of obesity and chronic disease research available, empowering healthcare providers—our own FlyteHealth clinicians and those of our healthcare partners—to deliver the highest standards of care, consistently. While others are jumping on the GLP-1 bandwagon, we see a better way. One that allows employers and payers to offer the best in obesity care, while keeping costs under control. FlyteHealth clinicians prescribe GLP-1 medications strategically, alongside lower-cost generics, for treatment that’s specific to what our patients’ bodies truly need and delivers better control over health care costs. Obesity care goes well beyond weight loss. FlyteHealth gives patients the power to achieve a lifetime of better health. Whether they are actively losing weight or maintaining a normal BMI, we deliver clinical care and coordinate with care teams to help them manage optimal health for life. At FlyteHealth, we’re committed to making sure nothing stands in the way of someone getting the care they need. Together, we’re a collective force for fighting chronic disease.

Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), enables us to deliver a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells, expanding the universe of druggable targets. Our team is committed to leveraging ARMMs technology to enable new therapies and address currently unmet medical needs.

Geneoscopy is a life sciences company with the mission to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Geneoscopy’s lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded a Breakthrough Device Designation from the FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Our initial prospective clinical study demonstrates that the diagnostic can detect these lesions with greater sensitivity than all existing noninvasive screening tests, thereby, serve as a potential aid in early detection and prevention of cancer. Geneoscopy is also developing diagnostics for the diagnosis and management of inflammatory bowel disease in partnership with biopharmaceutical companies and leading academic research institutions.

Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company that focuses on developing first-in-class breakthrough treatments for CLDN1+ tumors and organ fibrosis.  Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1.  Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors. In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver.  The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).  Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France. For more information, please visit us at www.alentis.ch or write to: info@alentis.ch

This page is intended for US audiences. Founded in 2019, NewAmsterdam Pharma Corporation is a late-stage clinical biopharmaceutical company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. The Company is investigating a selective cholesteryl ester transfer protein (CETP) inhibitor as an LDL-C lowering therapy for patients who cannot be treated optimally with currently available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally tolerated statin therapy.

Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is Pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently being evaluated for the treatment of Huntington’s disease in our global Phase 3 PROOF-HD trial, and for the treatment of ALS in the Phase 2/3 HEALEY platform trial. The company is led by Dr. Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S.

VaxEquity is a biotechnology company amplifying the impact of RNA vaccines and therapeutics, through using its next generation self-amplifying RNA (saRNA) platform. The Company uses saRNA to provide greatly enhanced protein expression, combining better tolerability with slower release and thermostability. VaxEquity is pioneering a next generation approach by modifying its saRNA to modulate the immune response and thereby overcoming current limitations. The flexibility of the Company’s platform ensures that its broad pipeline of assets can be designed, developed, and manufactured rapidly and at scale. VaxEquity was founded in 2020 by Professor Robin Shattock, the Head of Immunology of Infection at Imperial College London and is led by a world class team who are pioneers in the field of RNA.

Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with applications in a number of therapeutic indications such as septic shock or myocardial infarction. Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases.

ZielBio is a clinical-stage biotechnology company using groundbreaking technology to identify druggable and specific targets that have the potential to radically change how we treat disease. We are currently advancing several therapeutics to expand treatment options and meaningfully improve the live of patients with cancer.

IM Therapeutics is building an HLA-directed platform for new therapies. We have demonstrated early effectiveness in type 1 diabetes and are building a pipeline of targeted therapies across autoimmune diseases.

IM Therapeutics is building an HLA-directed platform for new therapies. We have demonstrated early effectiveness in type 1 diabetes and are building a pipeline of targeted therapies across autoimmune diseases.

Apic Bio is committed to finding cures for patients with genetic diseases.

We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be applied across a vast array of indications to create victories for patients most in need.

.

DeepCure discovers transformative small molecule therapies for immune and inflammatory diseases. The company uses a chemistry platform that combines AI, physics-based tools and automated chemical synthesis to identify truly novel molecules that address unsolved challenges in drug discovery. The pipeline includes an oral STAT6 program with multiple novel scaffolds and an oral BRD4(BD2) program with the first truly selective inhibitor. DeepCure expects to start in clinical trials in 2025.

FlyteHealth is a tech-enabled healthcare services organization born of the belief that everyone deserves to live a healthy life. Our efforts to bring the most effective health care to people with obesity, while making it cost-efficient to do so, mean that more people can transform their health for the better—now and for the rest of their lives. We were founded by physicians who were the first to recognize obesity not as a simple issue of willpower, but as a complex disease that requires expert medical treatment. Based on their decades of research and caring for patients, our clinically proven approach combines the latest in personalized medication therapy and behavior coaching that not only helps people lose weight for the long term, but significantly improves related conditions. Our obesity treatment platform, powered by Flyte Intelligence, is built from the largest data set of obesity and chronic disease research available, empowering healthcare providers—our own FlyteHealth clinicians and those of our healthcare partners—to deliver the highest standards of care, consistently. While others are jumping on the GLP-1 bandwagon, we see a better way. One that allows employers and payers to offer the best in obesity care, while keeping costs under control. FlyteHealth clinicians prescribe GLP-1 medications strategically, alongside lower-cost generics, for treatment that’s specific to what our patients’ bodies truly need and delivers better control over health care costs. Obesity care goes well beyond weight loss. FlyteHealth gives patients the power to achieve a lifetime of better health. Whether they are actively losing weight or maintaining a normal BMI, we deliver clinical care and coordinate with care teams to help them manage optimal health for life. At FlyteHealth, we’re committed to making sure nothing stands in the way of someone getting the care they need. Together, we’re a collective force for fighting chronic disease.

Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), enables us to deliver a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells, expanding the universe of druggable targets. Our team is committed to leveraging ARMMs technology to enable new therapies and address currently unmet medical needs.

Geneoscopy is a life sciences company with the mission to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Geneoscopy’s lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded a Breakthrough Device Designation from the FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Our initial prospective clinical study demonstrates that the diagnostic can detect these lesions with greater sensitivity than all existing noninvasive screening tests, thereby, serve as a potential aid in early detection and prevention of cancer. Geneoscopy is also developing diagnostics for the diagnosis and management of inflammatory bowel disease in partnership with biopharmaceutical companies and leading academic research institutions.

Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company that focuses on developing first-in-class breakthrough treatments for CLDN1+ tumors and organ fibrosis.  Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1.  Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors. In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver.  The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).  Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France. For more information, please visit us at www.alentis.ch or write to: info@alentis.ch